A study of the cerebral effect of pegylated interferon [peginterferon alfa 2b] in hepatitis C positive subjects

Trial Profile

A study of the cerebral effect of pegylated interferon [peginterferon alfa 2b] in hepatitis C positive subjects

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Most Recent Events

    • 21 Jul 2006 The expected completion date for this trial is now 1 Dec 2006.
    • 21 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top